دورية أكاديمية
أعرض في EDS

Drug-Induced Liver Injury During a Glaucoma Neuroprotection Clinical Trial.

التفاصيل البيبلوغرافية
العنوان: Drug-Induced Liver Injury During a Glaucoma Neuroprotection Clinical Trial.
المؤلفون: Shukla AG; Department of Ophthalmology, Columbia University Irving Medical Center, New York, NY., Cioffi GA, Liebmann JM
المصدر: Journal of glaucoma [J Glaucoma] 2024 Aug 01; Vol. 33 (8), pp. e58-e59. Date of Electronic Publication: 2024 Mar 28.
نوع المنشور: Journal Article; Case Reports
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 9300903 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-481X (Electronic) Linking ISSN: 10570829 NLM ISO Abbreviation: J Glaucoma Subsets: MEDLINE
أسماء مطبوعة: Publication: <2015- > : Philadelphia, PA : Wolters Kluwer Health, Inc.
Original Publication: New York, N.Y. : Raven Press, c1992-
مواضيع طبية MeSH: Chemical and Drug Induced Liver Injury*/etiology , Chemical and Drug Induced Liver Injury*/diagnosis , Chemical and Drug Induced Liver Injury*/prevention & control , Neuroprotective Agents*/adverse effects , Niacinamide*/adverse effects , Vitamin B Complex*/therapeutic use , Vitamin B Complex*/administration & dosage, Aged ; Female ; Humans ; Male ; Middle Aged ; Glaucoma/drug therapy ; Intraocular Pressure/drug effects ; Intraocular Pressure/physiology ; Clinical Trials as Topic
مستخلص: Abstract: There are several ongoing, worldwide clinical trials with a cumulative target enrollment of over 1300 participants on the role of nicotinamide (a specific form of vitamin B3) as a therapeutic neuroprotective treatment for glaucoma. We describe a serious adverse event of drug-induced liver injury (DILI) likely related to the use of 3 g/day nicotinamide in a glaucoma clinical trial (clinicaltrials.gov identifier: NCT05695027) based in the United States. This report is important to share with the medical community, as other participants in glaucoma nicotinamide trials globally may have similar adverse events and many patients are using nicotinamide as a health supplement without medical supervision. We recommend that investigators, physicians, and patients remain vigilant about DILI as they seek novel vision-preserving neuroprotective therapies.
Competing Interests: Disclosure: The authors declare no conflict of interest.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.
Williams PA, Harder JM, Foxworth NE, et al. Vitamin B(3) modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017;355:756–760.
Tribble JR, Otmani A, Sun S, et al. Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. Redox Biol. 2021;43:101988.
Williams PA, Harder JM, Cardozo BH, et al. Nicotinamide treatment robustly protects from inherited mouse glaucoma. Commun Integr Biol. 2018;11:e1356956.
Williams PA, Harder JM, Foxworth NE, et al. Nicotinamide and WLD(S) Act together to prevent neurodegeneration in glaucoma. Front Neurosci. 2017;11:232.
Williams PA, Harder JM, John SWM. Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in glaucoma. J Glaucoma. 2017;26:1161–1168.
Harder JM, Guymer C, Wood JPM, et al. Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin. Proc Natl Acad Sci U S A. 2020;117:33619–33627.
Jassim AH, Coughlin L, Harun-Or-Rashid M, et al. Higher reliance on glycolysis limits glycolytic responsiveness in degenerating glaucomatous optic nerve. Mol Neurobiol. 2019;56:7097–7112.
De Moraes CG, John SWM, Williams PA, et al. Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmol. 2022;140:11–18.
Liebmann JM, Cioffi GA. Nicking Glaucoma with Nicotinamide? N Engl J Med. 2017;376:2079–2081.
Osmond H, Hoffer A. Massive niacin treatment in schizophrenia. Review of a nine-year study. Lancet. 1962;1:316–319.
Winter SL, Boyer JL. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). N Engl J Med. 1973;289:1180–1182.
Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes. 1998;47:980–984.
Parsons WB Jr. Studies of nicotinic acid use in hypercholesteremia. Changes in hepatic function, carbohydrate tolerance, and uric acid metabolism. Arch Intern Med. 1961;107:653–667.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012:31643176.
سلسلة جزيئية: ClinicalTrials.gov NCT05695027
المشرفين على المادة: 0 (Neuroprotective Agents)
25X51I8RD4 (Niacinamide)
12001-76-2 (Vitamin B Complex)
تواريخ الأحداث: Date Created: 20240327 Date Completed: 20240814 Latest Revision: 20240815
رمز التحديث: 20240815
DOI: 10.1097/IJG.0000000000002394
PMID: 38536128
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-481X
DOI:10.1097/IJG.0000000000002394